| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| SAUNDERS BRENT L | Director | C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO | /s/ Kathleen Scott, Attorney-in-Fact | 22 May 2025 | 0001268854 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SPRY | Common Stock | Options Exercise | $121K | +120K | $1.01 | 120K | 20 May 2025 | Direct | ||
| transaction | SPRY | Common Stock | Sale | -$1.71M | -120K | -100% | $14.25 | 0 | 20 May 2025 | Direct | F1 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SPRY | Stock Option (Right to Buy) | Options Exercise | $0 | -120K | -20.31% | $0.00 | 471K | 20 May 2025 | Common Stock | 120K | $1.01 | Direct | F2 |
| Id | Content |
|---|---|
| F1 | The weighted average sale price for the transaction reported was $14.2502 and the range of prices were between $14.25 and $14.26. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| F2 | Immediately exercisable. |